Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
about
Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporinsUpdated functional classification of beta-lactamasesThree decades of beta-lactamase inhibitorsbeta-Lactamases in laboratory and clinical resistanceampG gene of Pseudomonas aeruginosa and its role in β-lactamase expressionBacterial temporal dynamics enable optimal design of antibiotic treatmentGenotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein.Molecular detection of antimicrobial resistanceCarbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein.In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.beta-Lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors.Virtual screening of AmpC/β-lactamase as target for antimicrobial resistance in Pseudomonas aeruginosaBeyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-LactamasesMechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.Structural features related to hydrolytic activity against ceftazidime of plasmid-mediated SHV-type CAZ-5 beta-lactamaseHigh-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrumTransient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis.Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France.Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.Current epidemiology and growing resistance of gram-negative pathogens.Identification of MupP as a New Peptidoglycan Recycling Factor and Antibiotic Resistance Determinant in Pseudomonas aeruginosa.Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.The use of the PhP-KE biochemical fingerprinting system in epidemiological studies of faecal Enterobacter cloacae strains from infants in Swedish neonatal wards.OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes.Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.AmpC beta-lactamases.Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibioticsOccurrence of bla DHA-1 mediated cephalosporin resistance in Escherichia coli and their transcriptional response against cephalosporin stress: a report from India.The penicillins today.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.β-lactam/β-lactamase inhibitor combinations: from then to now.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression.Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
P2860
Q24616317-F8794B40-6EB0-41CD-B918-0650864DF599Q24644798-AAA12D71-25A6-4B3F-A0AE-37CF1FA4546DQ24646623-AD76311F-024D-46ED-A5C0-4981D54FB00CQ24669605-C6952F80-D654-476C-981B-3F5C33B4DB8CQ28493038-577F45A9-95E4-43A1-A8C4-BEAAB2869547Q28546654-0A433600-0DEE-4827-BD21-6D978ACA9762Q30278439-EF13F790-0062-4E99-8BCB-E5920B0F8902Q33209766-7A328AC0-A69C-4587-B7F2-49AF4B130D58Q33422951-13FFD9F5-0935-47D1-B7C7-B344326E5B01Q33975793-97A67E3E-63BA-43ED-A00F-B5EBBE6F0806Q33976310-854C5BC2-24A9-41A4-8BD3-52BF6BE5399BQ33977338-34B71D9F-4145-40E9-8873-8776C29CAC46Q34074695-C5C4A4BE-691E-4192-8370-54E2C60342DAQ34214590-43F3252E-3199-4D85-8ED8-8E5411D27649Q34266074-9BC7CB22-ECB4-49B9-B7FF-BB7463462FB8Q34555131-EF17C5BD-DC98-4F2D-8913-585CEF0FD384Q34933120-18049D29-D2D0-40A2-8250-6C1A3AB1411AQ35344839-ADB37F84-A84C-4A09-9706-6D559589A03FQ35364989-99A11F0D-CC55-462F-BB7D-AE52289DB45EQ35843025-ED83A1DB-F30E-406A-90E7-57E65F45F266Q35884688-4F3055E9-2DC9-4180-9BC4-AE93A23C256CQ35892907-049FC712-29E9-40B5-91C8-4072E502FBFDQ35893975-076AEBDD-0B3C-4901-9BC2-C073D2D15E05Q35975439-00C720B6-AEE5-427E-89B1-69E7B192A069Q36025192-2810301B-B040-4DA0-879D-A8373B206E1BQ36326129-8796311C-3184-44B9-AEC9-936ACE865D11Q36496456-B6087523-9A0C-4CE1-8B78-83ABFFF55E03Q36505736-E84BB403-5867-4021-882C-D2C1A8076FC1Q36753213-F4429591-D485-403A-9358-77481882835BQ36754084-77479827-F72F-46E1-9927-6646ED8E4D57Q37119379-FED0DC83-D22D-4849-AAA8-9A1D7E5973C4Q37366249-2546C4CA-D6DD-4C9B-89F7-222BBD038949Q37680591-6A330DC2-ABA8-4B61-AF34-5F1755035C1BQ37713480-0269656A-6886-4CDF-AE0A-57D48E4D9FCEQ37940996-01F6C36B-5F93-4CB8-A269-9E17490EDC33Q37949391-FC6EEDB5-6421-4BC8-8FC9-89E44C4876DDQ38264182-0381BF3C-1D4D-4D55-83C0-C7540CD4BA7DQ38958278-4007829B-A9F6-479D-A65C-8622B94B5E3BQ39473061-E0EA4DFD-0407-45DF-9478-361D7A44ADFCQ39558488-9FCD3C2B-C36D-40F8-8081-81BBA59FF216
P2860
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Clinical significance of beta- ...... ression in gram-negative rods.
@en
Clinical significance of beta- ...... ression in gram-negative rods.
@nl
type
label
Clinical significance of beta- ...... ression in gram-negative rods.
@en
Clinical significance of beta- ...... ression in gram-negative rods.
@nl
prefLabel
Clinical significance of beta- ...... ression in gram-negative rods.
@en
Clinical significance of beta- ...... ression in gram-negative rods.
@nl
P2860
P356
P1476
Clinical significance of beta- ...... ression in gram-negative rods.
@en
P2093
D M Livermore
P2860
P304
P356
10.1007/BF02013107
P577
1987-08-01T00:00:00Z